XPeng Inc ADR (XPEV) concluded trading on Wednesday at a closing price of $20.37, with 6.32 million shares of worth about $128.64 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 69.05% during that period and on June 04, 2025 the price saw a gain of about 3.77%. Currently the company’s common shares owned by public are about 775.87M shares, out of which, 755.00M shares are available for trading.
Stock saw a price change of 5.38% in past 5 days and over the past one month there was a price change of 2.16%. Year-to-date (YTD), XPEV shares are showing a performance of 72.34% which increased to 145.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.60 but also hit the highest price of $27.16 during that period. The average intraday trading volume for XPeng Inc ADR shares is 10.96 million. The stock is currently trading 1.28% above its 20-day simple moving average (SMA20), while that difference is up 3.03% for SMA50 and it goes to 34.47% higher than SMA200.
XPeng Inc ADR (NYSE: XPEV) currently have 775.87M outstanding shares and institutions hold larger chunk of about 14.87% of that.
The stock has a current market capitalization of $15.81B and its 3Y-monthly beta is at 2.57. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 1.07 while making debt-to-equity ratio of 0.58. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XPEV, volatility over the week remained 3.32% while standing at 4.40% over the month.
Stock’s fiscal year EPS is expected to rise by 77.85% while it is estimated to increase by 196.46% in next year.
Coverage by Nomura stated XPeng Inc ADR (XPEV) stock as a Buy in their note to investors on March 19, 2025, suggesting a price target of $30 for the stock. On March 19, 2025, Daiwa Securities Downgrade their recommendations, while on March 10, 2025, Citigroup Upgrade their ratings for the stock with a price target of $29. Stock get a Neutral rating from UBS on February 24, 2025.
